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Abstract 
Introduction. Mucoepidermoid carcinoma (MEC) is the most common malignancy of the 
salivary glands whose clinical behavior is largely unpredictable, ranging from indolent tumor 
growth to highly aggressive metastatic spread. The objective of this study was to determine the 
clinicopathologic predictors of recurrence and survival in patients with head and neck MEC. 
Materials and Methods. The medical records of 64 patients who underwent surgical treatment 
for head and neck MEC between 1982 and 2010 were reviewed. Main outcome measures were 
disease-free survival (DFS) and overall survival (OS). Clinicopathologic parameters evaluated 
were age, gender, anatomic subsite, histological grade, tumor stage, tumor size, adjuvant therapy, 
nodal and margin status. 
Results. Of the 64 patients, 33 parotid glands, 10 submandibular/sublingual, 21 minor salivary 
glands MEC (17 oral cavity and 4 maxillary sinus) primaries were identified and surgically 
treated. Twenty-one (32.8%) patient underwent postoperative radiotherapy. The 5-year DFS and 
OS for the entire cohort were 79.7%, and 67.2%, respectively. Histological grade, tumor stage 
and nodal status were a statistically significant predictor of DFS and OS. Furthermore, 
anatomical subsite and patient age were statistically significant predictors with respect to OS. 
There was no statistically significant difference in DFS or OS based on gender, adjuvant therapy, 
tumor size and margin status. 
Conclusion. Advanced tumor stage, high histologic grade, submandibular/sublingual localization 
and positive nodal status were independent predictors of prognosis in patients with head and neck 
MEC. Further studies into the molecular biology of MEC are needed in order to provide new 
therapeutic strategies in patients with locally aggressive and highly metastatic carcinomas. 
Introduction 
 
Mucoepidermoid carcinoma (MEC) is the most common malignancy of the salivary glands, 
representing 30-40% of all major salivary gland malignancies and up to half of parotid gland 
malignancies.
1, 2 
The clinical behavior of MEC is highly variable, ranging from indolent tumor 
growth to highly aggressive metastatic carcinomas. In order to clarify its largely unpredictable 
behavior, a different prognostic factors have been studied. Although inconsistently, conventional 
clinicopathologic parameters such as age, gender, tumor site, stage, TNM status, extracapsular 
spread (ECS), adjuvant therapy, and margin status have been shown to have predictive value with 
respect to survival.
3-5
 However, it has been generally accepted that the most relevant 
prognosticators of survival are tumor grade and disease stage.
4, 6-7 
The aim of this study was to 
describe head and neck MEC treated at a tertiary care hospital centre, as well as to determine the 
clinicopathologic predictors of recurrence and survival in this patient population. 
  
Materials and methods 
Using retrospective chart review, data collected included age, gender, tumor site, histological 
grade, stage, type of treatment modality, nodal status, histological status of surgical margins, 
disease status, and follow-up. 
The study included 64 patients with head and neck MEC. Inclusion criteria were: histologically 
proven and surgically treated head and neck MEC. Patients with adverse histopathological 
features (high grade tumors, positive margin, perineural invasion, extracapsular spread (ECS), 
multiple positive lymph nodes, stage T3 or T4) underwent postoperative irradiation. MEC were 
staged according to TNM classification of malignant tumors of salivary glands. 
In our institution MEC is graded into low grade (LG), intermediate grade (IMG) and high grade 
(HG) carcinomas according to WHO classification
 
and includes following data: amount of cystic 
component, presence of neural invasion, necrosis, number of mitoses per 10 high power field 
(HPF) and presence or absence of anaplasia.
8
 All of the listed data get their matching number of 
points, which all add together. The obtained point score responds to tumor grade, which in case 
of mucoepidermoid carcinoma can be low, intermediate and high grade. None of the patients was 
lost to follow-up. 
Statistical analysis 
To assess the association of clinicopathological parameters, a χ2-test or Fisher’s exact test were 
performed. The primary endpoints were disease-free survival (DFS) and overall survival (OS). 
Follow-up intervals were calculated in months from the date of first date of surgical treatment to 
the date of last follow-up or death. A DFS event was defined as a pathologically confirmed 
recurrence; an OS event was defined as death from any cause; deaths from other causes were 
censored at the date of death. Patients with IMG-MEC were affiliated to LG-MEC due to small 
sample size in IMG group and similar biological behavior between these two histological 
subtypes.  DFS and OS curves were estimated by the Kaplan-Meier method while the log-rank 
test has been used to test differences between the actuarial curves. All statistics was done using 
Statistica, data analysis statistical software (StatSoft, Inc version 10, 2011). P values of <0.05 
were considered statistically significant. 
  
Results 
There were 28 (43.7%) women and 36 (56.3%) men, with a mean age at diagnosis of 46.9 (range 
9-80 years). Sixty (93.8%) previously untreated patients presented to our institution, while 4 
patients (6.2%) were referred to our hospital due to recurrent tumors. Of previously untreated 
tumors, 44 patients had stage T1/T2, 15 had advanced disease (T3/T4) whereas 5 patients had 
unknown disease stage. The parotid gland was the most frequent primary tumor site. 
Clinicopathological characteristics of the study group are summarized in Table 1. 
The 5-year OS for the entire cohort were 67.2%. The 5-year DFS was 79.7% with 13 (20.3%) 
patients developing recurrence. Univariate analysis showed that advanced histological grade and 
positive nodal status were a statistically significant predictor of DFS and OS (Figure 1-4). 
Furthermore, anatomical subsite, tumor stage and patient age were statistically significant 
predictor with respect to OS. There was no statistically significant difference in DFS or OS based 
on gender, adjuvant therapy, and margin status. 
Of 64 patients, 39 (60.9%) had low-grade (LG), 6 (9.4%) had intermediate-grade (IMG) and 19 
(29.7%) had high grade (HG) MEC. The influence of histological grade on survival is shown in 
Figure 1, and their correlation on other clinicopathological parameters is summarized in Table 2. The 
5-year DFS and OS was 97.4% and 82.1% in LG-MEC group compared to 83.3% and 50% in IMG-
MEC group and 42.1% in HG-MEC group respectively. There was significant difference in survival 
when comparing LG/IMG-MEC compared to cohort with HG-MEC (p=0.003). In addition, higher 
histological grade statistically significant correlated with advanced tumor stage (p=0.006), positive 
nodal status (p<0.001) and submandibular/sublingual subsite of the tumor (p=0.003).  
Twenty-one (32.8%) patient underwent postoperative radiation. Thirteen (20.3%) patients 
developed tumor recurrence following treatment in our institution. Four patients developed local 
recurrence, 5 regional and 4 distant metastases. 
Twenty-one (32.8%) patients died during 5-year follow-up period. Seven (33.3%) of them died 
due to tumor recurrence and 14 (66.4%) died of other causes. 
Follow-up information was available for all patients, range from 3 – 171 months. 
  
Discussion 
In this study we reported 28 year single-institution's experience on 64 patients with head and 
neck MEC. In our study, head and neck MEC occurred most often in the fifth decade of life and 
had a slight male predominance which is similar to prior reports.
9-10
 The 5-year of the cohort OS 
was 67%, which is consistent with prior studies.
10-12
 
On univariate analysis, features that correlated with significantly poorer survival were higher 
histological grade, advanced tumor stage, submandibular/sublingual localization and positive 
nodal status. 
Tumor stage and histological grade appear to have significant impact on survival. We confirmed 
a significant decrease in survival for patients with T3/T4 tumors as well as presence of nodal 
disease. This is in accordance with previous findings in the literature.
6, 13 
Past reports indicated trend toward poorer survival when stratified according to grade status.
8, 14-15
 
LG-MEC characteristically shows better prognosis with lower recurrence and metastatic potential 
compared to HG-MEC. Due to less aggressive clinical course, LG-MEC is often treated with 
surgical excision with negative margins solely, while aggressive HG-MEC are treated in 
combination of surgery, neck dissection and post-operative adjuvant radiotherapy.
16
 Three 
grading system was introduced raising major point about clinical behavior and prognosis of IMG-
MEC.
17
 Some studies have demonstrated that there is no significant difference in survival (DFS 
and OS) between LG and IMG-MEC group of patients, but significant difference between IMG 
and HG-MEC suggesting that IMG-MEC have similar clinical behavior to LG-MEC.
6, 18-19
 
Similarly, our analysis showed difference in survival when comparing LG/IMG tumors and HG-
MEC. Tumor subsite appears to have significant impact on survival, showing that 
submandibular/sublingual localization had the worst prognosis compared to parotid or other 
minor gland MEC regardless on tumor grade or extend of treatment. This finding is in accordance 
with prior studies.
13, 20-21
 Also submandibular/sublingual MEC in our study tends to developed in 
older patients with larger size tumors comparing to other MEC patients. 
In contrast to most solid human tumors, MEC is frequently characterized by chromosomal 
translocation. This includes t (11;19) (q21–22; p13) translocation resulting in a CRTC1-MAML2 
gene fusion.
22-23
 
The fusion positive cases show significantly higher survival rates compared to fusion-negative 
cases, representing prognostic marker in patients with MEC.
22, 24-26 
Furthermore, preliminary 
studies using molecule inhibitors of the epidermal growth factor receptor (EGFR) or protein 
kinase pathways have shown inhibition proliferation of MEC cell lines in vitro, suggesting that 
targeting these pathways may offer a new treatment approach in CRTC1-MAML2 MECs positive 
patients.
27 
Although MEC is the most common salivary gland carcinoma, only few studies have addressed 
the role of systemic therapy in adjuvant and palliative settings. While addition of high-dose 
chemotherapy to radiation (concurrent chemoradiotherapy) in head and neck squamous cell 
carcinoma has led to significant survival improvement compared to radiation solely, the efficacy 
of chemotherapy seems to be limited in HG-MEC in both curative and palliative settings. 
The retrospective type of the study represents the primary limitation of the study. In addition, this 
study includes time period from 1982 to 2015. During this time, treatment modalities have 
evolved. As such, the management of the study population is not homogeneous and may 
influence final outcome and the results obtained from statistical analysis. Additionally, the study 
could not be strengthened by a meta-analysis due to the small sample size. 
In conclusion, this study shows that advanced tumor stage, high histological grade, 
submandibular/sublingual localization and positive nodal status were unfavorable prognostic 
factors in patients with head and neck MEC. Further investigations are needed in order to provide 
new prognostic factors and therapeutic strategies in head and neck MEC. 
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Table 1. Clinicopathological characteristics of mucoepidermoid 
carcinoma 
 
 
Baseline Characteristic Number of Patients (%) 
Mean age (years) 46.9 
Gender  
Male 36 (56.3) 
Female 28 (43.7) 
Tumor subsite  
Parotid gland 33 (51.6) 
Submandibular/sublingual  gland  10 (15.6) 
Minor gland 21 (32.8) 
Histological grade  
Low grade 39 (60.9) 
Intermediate grade 6 (9.4) 
High grade 19 (29.7) 
Tumor stage  
T1/T2 44 (68.8) 
T3/T4 15 (23.4) 
Unknown 5 (7.8) 
Nodal status  
Negative 50 (78.1) 
Positive 14 (21.9) 
Margin status  
Negative 56 (87.5) 
Positive 7 (10.9) 
Unknown 1 (1.6) 
Radiation therapy  
No 43 (67.2) 
Yes 21 (32.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Histological grade and thier influence on other clinicopathological paremeters 
 
 
Histological grade 
Low 
(N=39) 
Intermediate 
(N=6) 
High 
(N=19) 
p value 
Mean age (years) 42.74 49.83 54.63 n.s.
1
 
Gender     
Male 19 (48.7%) 4 (66.7%) 13 (68.4%) n.s.
2
 
Female 20 (51.3%) 2 (33.3%) 6 (31.6%)  
Tumor stage     
T1/T2 33 (84.6%) 4 (66.7%) 7 (36.8%) 0.006
2
 
T3/T4 4 (10.3%) 2 (33.3%) 9 (47.4%)  
Unknown 2 (5.1%) 0 3 (15.8%)  
Nodal status     
Negative 39 (100.0%) 3 (50.0%) 8 (42.1%) <0,001
2
 
Positive 0 3 (50.0%) 11 (57.9%)  
     
DFS 38 (97.4%) 5 (83.3%) 8 (42.1%) <0,001
2
 
     
    OS 32 (82.1%) 3 (50.0%) 8 (42.1%) 0.006
2
 
     
1
 Oneway analysis of variance, 
2
 χ2 – test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3. Tumor subsite and thier influence on other clinicopathological paremeters 
 
 
Tumor subsite 
Parotid gland 
MEC (N=33) 
Submand/subling 
gland MEC (N=10) 
Minor gland 
MEC (N=21) 
p value 
Mean age (years) 49.67 61.10 35.90 0.003
1
 
Tumor size (mm) 27.03 35.50 21.68 n.s.
2
 
Gender     
Male 16 (48.5%) 9 (90.0%) 11 (52.4%) n.s.
3
 
Female 17 (51.5%) 1 (10.0%) 10 (47.6%)  
Histological grade     
Low 17 (51.5%) 2 (20.0%) 20 (95.2%) 0.003
3
 
Intermediate 4 (12.1%) 2 (20.0%) 0  
High 12 (36.4%) 6 (60.0%) 1 (4.8%)  
Tumor stage     
T1/T2 24 (72.7%) 4 (40.0%) 16 (76.2%) n.s.
3
 
T3/T4 6 (18.2%) 6 (60.0%) 3 (14.3%)  
Unknown 3 (9.1%)                   0 2 (9.5%)  
Nodal status     
Negative 25 (75.8%) 4 (40.0%) 21 (100.0%) 0.001
3
 
Positive 8 (24.2%) 6 (60.0%) 0  
     
DFS 23 (69.7%) 8 (80.0%) 20 (95.2%) n.s.
3
 
     
     
OS 21 (63.6%) 3 (30.0%) 19 (90.5%) 0.003
3
 
     
1
 Oneway analysis of variance, 
2
 Kruskal-Wallis test, 
3
 χ2 – test 
 
 
  
Fig. 1 Kaplan-Meier curve of 5-year OS comparing histological grade 
 
 
  
  
Fig. 2 Kaplan-Meier curve of 5-year OS comparing anatomical subsite 
 
 
 
  
Fig. 3 Kaplan-Meier curve of 5-year OS comparing tumor stage 
 
  
  
Fig. 4 Kaplan-Meier curve of 5-year OS comparing nodal status 
 
 
 
